Pfizer (PFE)

The sleeper story is Pfizer's permanent transformation from a COVID giant back to a focused pharma company, with the $7.3B recently launched/acquired portfolio now carrying the growth burden but decelerating. The Metsera bidding war exposes obesity desperation, though the unprecedented FTC clearance suggests either inside track or regulatory blessing. The binding constraint isn't capital allocation - it's execution velocity on pipeline programs where FDA is clearly tightening standards. Bourla's most revealing moment: 'What they want is to catch and kill an emerging competitor' - pure projection about their own obesity fears. My view changes if the recently launched portfolio growth drops below 5% or if Metsera shareholders surprisingly vote down the deal despite FTC clearance.